# SECOMBIT (NCT02631447)

> Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02631447
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Fondazione Melanoma Onlus
- Conditions: Metastatic Melanoma
- Interventions: LGX818; MEK162; Nivolumab; Ipilimumab
- Enrollment: 251
- Primary outcome: Overall Survival

## Commentary we found

- Podcasts: 12
- YouTube: 11
- X threads: 6

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=secombit-nct02631447

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02631447", "email": "<work email>"}; the inbox owner confirms by the emailed link.